Gale will report the results of the ASC22 (Envolimab) chronic hepatitis B phase IIa study at the 2021 American Association for the Study of Liver Diseases Annual Meeting

Hangzhou and Shaoxing, October 12, 2021/PRNewswire/ - Golly Pharmaceutical Co.
, Ltd.
(Hong Kong Stock Exchange code: 1672) today announced its subcutaneous injection of PD-L1 antibody ASC22 (Envolimab) chronic type B The results of the phase IIa hepatitis study will be reported in the form of an oral report at the 2021 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting® 2021)
.

"I am very pleased that the abstract of the Phase IIa clinical trial of ASC22 chronic hepatitis B has been selected as the oral report of the American Association for the Study of Liver Diseases," said Dr.
Wu Jinzi, the founder, chairman and CEO of Geli.
"We believe that with good IIa Based on the long-term data and its advantages in terms of safety and convenience, this first-in-class immunotherapy has great potential in the functional cure of chronic hepatitis B.

"

The abstract that will be presented at the annual meeting of the American Association for the Study of Liver Diseases in 2021 is as follows:

Report format: Parallel Session, Oral Report Abstract Number: 91 Conference Topic: Parallel Session 13: New Hepatitis B Therapy and Strategies Speaker: Professor Wang Guiqiang, Peking University First Hospital Reporting Time: November 14, 2021 Eastern Standard Time, Sunday, 10:00-11:30 AM Key information: ASC22 (Envolimab) is a PD-L1 monoclonal antibody injected subcutaneously
.

About songli

Golly is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.
HK)
.

1.
Non-alcoholic steatohepatitis: Gan Lai Pharmaceutical, a wholly-owned subsidiary of Golly Pharmaceuticals Co.
, Ltd.
, focuses on the development and commercialization of innovative drugs in the field of non-alcoholic steatohepatitis
.

Source: Golly Pharmaceutical Co.